SimonMed, one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States, announced its implementation of SyntheticMR’s SyMRI software to support enhanced lesion detection and allow for quantitative MRI including the tracking of myelin development in pediatric patients and patients with Multiple Sclerosis.
“The quantification of myelin through SyntheticMR is an example of our rapid progress beyond 3T MRI to use the latest MR technology to further improve diagnoses,” said Dr. John Simon, MD, Chief Executive of SimonMed. “I expect the partnership with SyntheticMR will yield many new technologies that will quickly improve patient care.”
“SyntheticMR is excited to partner with SimonMed.” says Kyle Frye, President, SyntheticMR Inc. “Dr. Simon and his team understand the value of continuously offering patients and their referring providers best in class technology that has the patients experience at the forefront of what they do. SimonMed will be utilizing our tissue segmentation and myelin quantification across multiple sites and states, allowing for a truly integrated solution.”
Ad Statistics
Times Displayed: 173712
Times Visited: 3172 For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
About SyntheticMR AB
SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB’s product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan. The product is available in different packages. SyMRI IMAGE supports faster MRI workflows and improved patient throughput. SyMRI NEURO delivers automatic segmentation of brain tissue, supporting objective decision support. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden.
